TMS denied as experimental or investigational by Humana?

Humana's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies TMS as Experimental or Investigational

Humana's "experimental or investigational" denial for TMS typically means Humana's current coverage policy has classified TMS — or a specific TMS application — as not having sufficient evidence to be considered proven, effective, and appropriate for coverage. This is a particularly important denial to challenge because TMS has FDA clearance for specific indications, meaning it has met the regulatory standard for safety and effectiveness for those uses. An experimental denial should be examined closely to determine whether Humana's policy is outdated, whether it applies to a cleared indication or an off-label use, and whether Humana's clinical evidence standards are consistent with what federal parity law requires.

## Your Appeal Rights

Under ACA §2719 and ERISA §503, you are entitled to a full internal appeal and an independent external review if the internal appeal fails. External review is especially powerful in experimental-denial cases because the independent reviewer applies objective clinical evidence standards — not Humana's internal policy. You typically have approximately 180 days from the denial to file an internal appeal. Expedited review is available if standard timelines would seriously jeopardize your health. Importantly, you may also raise a Mental Health Parity and Addiction Equity Act (MHPAEA) argument: if Humana covers comparable procedures for physical health conditions that are at a similar evidence level, federal law may require equivalent treatment of this mental health procedure.

## What to Gather

• FDA clearance documentation: Confirmation that the specific TMS device and the specific indication for which you are being treated have FDA clearance.
• Humana's current coverage policy: Request the full text of Humana's TMS coverage policy and identify the evidence standard they apply. Note the date of the policy — policies that have not been updated may not reflect current clinical evidence.
• Treating clinician letter: Your psychiatrist or TMS provider should write a letter citing the clinical evidence base for TMS in your indication, referencing relevant professional society guidelines (without quoting statistics), and explaining how your case meets the standard of care.
• MHPAEA parity request: Ask Humana in writing to identify the evidence standard it applies to comparable medical/surgical procedures and whether TMS is being held to a higher standard than analogous physical-health treatments.

## Criteria-Mapping Structure

| Humana's Experimental Basis | Your Rebuttal | |---|---| | Evidence standard cited in policy | [Quote from Humana policy] | | FDA clearance for your indication | [Device clearance documentation] | | Professional society recognition | [Prescriber letter referencing relevant guidelines] | | MHPAEA parity comparison | [Comparable physical-health procedure Humana covers at similar evidence level] |

External review has a meaningful success rate for experimental denials involving procedures that have obtained FDA clearance, particularly when the independent reviewer applies a standard evidence-based medicine framework.